Similar articles for PMID: 31288537

Year	Number of Results
1989	1
1990	1
1996	1
1998	1
2000	4
2001	1
2002	1
2003	2
2004	1
2005	2
2006	2
2007	3
2008	3
2009	5
2010	3
2011	5
2012	5
2013	11
2014	5
2015	6
2016	5
2017	3
2018	8
2019	7
2020	12
2021	3
2024	0

1

Three-year events and mortality in cardiovascular disease patients without lipid-lowering treatment.

Dégano IR, Ramos R, García-Gil M, Zamora A, Comas-Cufí M, Francés A, Garcia-Elias A, Marrugat J. Dégano IR, et al. Eur J Prev Cardiol. 2020 Dec;27(19):2102-2104. doi: 10.1177/2047487319862103. Epub 2019 Jul 9. Eur J Prev Cardiol. 2020. PMID: 31288537 No abstract available.

2

Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis.

Masson W, Lobo M, Siniawski D, Molinero G, Huerín M, Nogueira JP. Masson W, et al. High Blood Press Cardiovasc Prev. 2019 Aug;26(4):263-272. doi: 10.1007/s40292-019-00330-8. Epub 2019 Jul 16. High Blood Press Cardiovasc Prev. 2019. PMID: 31313082

3

[Update of lipid lowering therapy].

Riesen WF, Mordasini RC. Riesen WF, et al. Praxis (Bern 1994). 2008 Nov 5;97(22):1179-84. doi: 10.1024/1661-8157.97.22.1179. Praxis (Bern 1994). 2008. PMID: 18979436 German.

4

Relation between baseline LDL-cholesterol and cardiovascular outcomes in high cardiovascular risk hypertensive patients: A post-hoc SPRINT data analysis.

Nguyen LS, Procopi N, Salem JE, Squara P, Funck-Brentano C. Nguyen LS, et al. Int J Cardiol. 2019 Jul 1;286:159-161. doi: 10.1016/j.ijcard.2019.01.048. Epub 2019 Jan 15. Int J Cardiol. 2019. PMID: 30685099 Free article. Clinical Trial.

5

Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.

García Ruiz FJ, Marín Ibáñez A, Pérez-Jiménez F, Pintó X, Nocea G, Ahumada C, Alemao E, Yin D; REALITY Study Group. García Ruiz FJ, et al. Pharmacoeconomics. 2004;22 Suppl 3:1-12. doi: 10.2165/00019053-200422003-00002. Pharmacoeconomics. 2004. PMID: 15669149 Clinical Trial.

6

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL. Cziraky MJ, et al. J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. J Manag Care Pharm. 2008. PMID: 19891279 Review.

7

Efficacy of more intensive lipid-lowering therapy on cardiovascular diseases: a systematic review and meta-analysis.

Hsu HY, Lin CJ, Lee YS, Wu TH, Chien KL. Hsu HY, et al. BMC Cardiovasc Disord. 2020 Jul 13;20(1):334. doi: 10.1186/s12872-020-01567-1. BMC Cardiovasc Disord. 2020. PMID: 32660417 Free PMC article.

8

Impact of using different SCORE tables for estimating cardiovascular risk.

Brotons C, Moral I, Soriano N, Cuixart L, Osorio D, Bottaro D, Puig M, Joaniquet X, Marcos A, Casasa A. Brotons C, et al. Rev Esp Cardiol (Engl Ed). 2014 Feb;67(2):94-100. doi: 10.1016/j.rec.2013.06.018. Epub 2013 Nov 19. Rev Esp Cardiol (Engl Ed). 2014. PMID: 24795115

9

Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study.

Johannesen CDL, Langsted A, Mortensen MB, Nordestgaard BG. Johannesen CDL, et al. BMJ. 2020 Dec 8;371:m4266. doi: 10.1136/bmj.m4266. BMJ. 2020. PMID: 33293274 Free PMC article.

10

Lipid-lowering therapy in low-risk patients.

Pearson TA. Pearson TA. JAMA. 1998 May 27;279(20):1659-61. doi: 10.1001/jama.279.20.1659. JAMA. 1998. PMID: 9613918 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

92 results

Results by year